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Abstract
Background: Earlier we have shown that extracellular sphingosine-1-phosphate (S1P) induces migration of human
pulmonary artery endothelial cells (HPAECs) through the activation of S1P1 receptor, PKCe, and PLD2-PKCf-Rac1 signaling
cascade. As endothelial cells generate intracellular S1P, here we have investigated the role of sphingosine kinases (SphKs)
and S1P lyase (S1PL), that regulate intracellular S1P accumulation, in HPAEC motility.
Methodology/Principal Findings: Inhibition of SphK activity with a SphK inhibitor 2-(p-Hydroxyanilino)-4-(p-Chlorophenyl)
Thiazole or down-regulation of Sphk1, but not SphK2, with siRNA decreased S1Pint, and attenuated S1Pext or serum-induced
motility of HPAECs. On the contrary, inhibition of S1PL with 4-deoxypyridoxine or knockdown of S1PL with siRNA increased
S1Pint and potentiated motility of HPAECs to S1Pext or serum. S1Pext mediates cell motility through activation of Rac1 and
IQGAP1 signal transduction in HPAECs. Silencing of SphK1 by siRNA attenuated Rac1 and IQGAP1 translocation to the cell
periphery; however, knockdown of S1PL with siRNA or 4-deoxypyridoxine augmented activated Rac1 and stimulated Rac1
and IQGAP1 translocation to cell periphery. The increased cell motility mediated by down-regulation was S1PL was pertussis
toxin sensitive suggesting ‘‘inside-out’’ signaling of intracellularly generated S1P. Although S1P did not accumulate
significantly in media under basal or S1PL knockdown conditions, addition of sodium vanadate increased S1P levels in the
medium and inside the cells most likely by blocking phosphatases including lipid phosphate phosphatases (LPPs).
Furthermore, addition of anti-S1P mAb to the incubation medium blocked S1Pext or 4-deoxypyridoxine-dependent
endothelial cell motility.
Conclusions/Significance: These results suggest S1Pext mediated endothelial cell motility is dependent on intracellular S1P
production, which is regulated, in part, by SphK1 and S1PL.
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Introduction
Sphingolipid metabolites such as ceramides and sphingoid bases
are important modulators of cell survival, cell proliferation,
angiogenesis, and vascular integrity. Among the various sphingo-
lipids, sphingosine-1-phosphate (S1P), elicits a plethora of cellular
responses such as proliferation, survival, chemotaxis and endothe-
lial barrier regulation. S1P is a naturally occurring bioactive lipid
found in nanomolar to micromolar concentrations in plasma and
serum [1], and exerts its cellular responses through ligation to G-
protein coupled S1P receptors, S1P1–5 that have been identified
[2]. S1P receptors (S1PR) are differentially expressed in various
cell types and are coupled to three distinct G-protein subfamilies,
including Gi,G q and G12/13. S1PR activation results in down-
stream activation of Rho-GTPases, cytoskeletal reorganization,
adherens and tight junction assembly, and focal adhesion
formation [3–6]. It is well established that S1P is a potent
angiogenic and vascular maturation factor regulating endothelial
cell proliferation, migration and remodeling [7–9]. Several
signaling pathways including changes in [Ca
2+]i, activation of
phosphatidylinositol 3-kinase, Akt, MAPKs, Rac1 and PKC have
been implicated in S1P-induced EC migration [2,10,11]. We have
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16571recently shown that S1P signals through S1P1 and Gi to activate
PKC-e and subsequently, a PLD2-PKC-f-Rac1 cascade to induce
migration of human lung ECs [12]. These studies strongly suggest
a role for extracellular action of S1P through S1P1 and other S1P-
Rs in stimulating migration of ECs.
In addition to S1P’s extracellular action, there is evidence that
supports an intracellular role of S1P in calcium release [13,14] and
modulation of histone acetylation via HDACs in breast cancer
cells [15]. Cellular S1P levels are regulated by its synthesis and
catabolism. Sphingosine kinases (SphKs) 1 and 2 catalyze the
phosphorylation of sphingosine (Sph) to S1P [16–18] while S1P is
degraded back to Sph by S1P phosphatases 1 and 2 and lipid
phosphate phosphatases [19–21] or to hexadecenal and ethanol-
amine phosphate by S1P lyase (S1PL) [22–25]. Availability of Sph
is the rate limiting step in intracellular generation of S1P, and Sph
is derived either from ceramides through ceramidases or from
circulating plasma S1P through ecto-LPPs [21,26]. Recent studies
show that human lung ECs have the ability to utilize exogenously
added S1P to generate intracellular S1P by hydrolysis to Sph
catalyzed by LPPs and subsequent phosphorylation by SphKs
[19]. In addition to these two pathways, S1P can also be generated
in plasma by lysophospholipase D/autotaxin-mediated hydrolysis
of sphingosylphosphorylcholine [27]; however, it is unclear if this
pathway is a major source of plasma S1P.
The role of intracellular S1P or enzymes regulating the generation
of cellular S1P in modulating cellular responses such as motility and
proliferation is yet to be well established. Very little is known on
intracellular targets of S1P and recent reports indicate potential
interaction between S1P and histone deacetylase 2 in breast cancer
cells [15] and S1P as a missing co-factor for E3 ubiquitin ligase
TRAF2 in HEK 293 cells [28]. Further, part of the intracellularly
generated S1P could be released by an ATP-binding cassette
transporter, ABCC1, which may subsequently activate S1PRs in an
autocrine or paracrine manner [29]. While platelets [30] and mast
cells [29] have been shown to release S1P upon activation, human
lung ECs released very little S1P under basal condition [31].
However, laminar shear stress leads to an increase in S1P release
from ECs suggesting vascular endothelium as an important source of
circulating S1P [32]. Interestingly, over-expression of SphK1 and
SphK2 enhanced accumulation of intracellular S1P while knock-
down of SphK1, but not SphK2, by siRNA decreased intracellular
S1P production from extracellular S1P [19]. Conversely, down-
regulation of S1PL with siRNA increased intracellular generation of
S1P in the presence or absence of extracellular S1P in HPAECs [19].
As over-expression of SphKs or down-regulation of S1PL modulated
S1P-induced human lung EC migration suggesting a potential role of
SphKs and S1PL in cell motility, in the present study, we examined
the role of SphKs and S1PL in human lung EC motility. Down-
regulation of SphK1, but not SphK2, by siRNA as well as over-
expression of SphK1 mutant attenuated intracellular S1P levels and
serum- and S1P-induced migration of human pulmonary artery
endothelial cells (HPAECs). However, knockdown of S1PL with
siRNA enhanced intracellular S1P and the serum- and S1P-induced
motility. Further, down-regulation of S1PL stimulated redistribution
of Rac1 and IQGAP1 to cell periphery compared to scrambled
siRNA transfected cells suggesting a potential role of intracellular S1P
in regulating Rac1/IQGAP1 signaling and migration.
Results
Involvement of SphK1, but not SphK2, in Extracellular
S1P-induced Wound Healing
Human pulmonary artery endothelial cells express SphK1 and
SphK2 [19], and to determine the role of SphK1 and SphK2 in
extracellular S1P (S1Pext)-induced migration, we employed an
inhibitor of SphK to block S1P formation. Pretreatment of
HPAECs with SphK inhibitor CII (10 mM) for 1 h, attenuated S1P
(1 mM) mediated migration as determined by wound healing assay
(Fig. 1A). The efficacy of CII was verified by measuring S1P
formation in cells exposed to Sph. As shown in Fig. 1B, HPAECs
that were pretreated with CII (10 mM) for 1 h showed diminished
formation of S1P from Sph as compared to control cells. As CII
blocks both SphK1 and SphK2 activities [39], role of SphK1 and
SphK2 was investigated using siRNA specific for SphK1 or
SphK2 to down-regulate the protein expression. Transfection of
cells with SphK1 or SphK2 siRNA (50 nM) for 48 h knocked
down .70% of SphK1 or SphK2 expression, as determined by
Western blotting (Fig. 2A and 2B). The specificity of SphK1 or
SphK2 siRNA is evidenced by down-regulation of mRNA
expression for the specific SphK isoform without affecting the
other (Fig. 2C and 2D). However, the SphK1 siRNA caused
,40% reduction of SphK1 mRNA (Fig. 2C). Presumably, at least
three reasons may account for this discordant mRNA and protein
expression in human lung ECS. First, there are many complicated
and varied post-transcriptional mechanisms involved in regulating
mRNA into protein; second, proteins may differ in their in vivo half
lives; and third, significant amount of error and noise in both
protein and mRNA experiments. Down-regulation of SphK1
(50 nM), but not SphK2, for 48 h attenuated S1P-induced
migration as determined by ECIS wound healing assay (Fig. 2E
and 2F). Further, treatment of cells with SphK1 or SphK2 siRNA
decreased intracellular S1P (S1P, fmol/nmol lipid P: scrambled
siRNA, 348.0613; SphK1 siRNA, 161611; SphK2 siRNA,
196611) as well as DHS1P levels (data not shown). Next, we
tested the ability of exogenous sphingosine (Sph) to induce EC
migration. Addition of exogenous Sph (1 mM) to wounded cells
induced migration (16 h) that was significantly less compared to
exogenous S1P (1 mM) (Closure of wounded area (%): Veh,
32612; Sph, 5669; S1P, 94615). Similarly, exogenous Sph-
induced cell migration as determined by ECIS wound healing
assay was lower compared to S1P (data not shown). These results
demonstrate that SphK1, but not SphK2, regulates S1Pext
mediated endothelial cell migration.
Sphingosine-1-phosphate lyase siRNA or 4-
Deoxypyridoxine Enhances Extracellular S1P-induced
HPAEC Wound Healing and Migration
Having established that blocking SphK1 decreases intracellular
S1P levels and attenuates cell migration, next we investigated the
role of sphingosine-1-phosphate lyase (S1PL), a pyridoxal
phosphate dependent enzyme, in S1Pext mediated cell motility
and wound healing. S1PL expression was down-regulated with
siRNA or activity was blocked with 4-deoxypyridoxine (4-DP), an
analog of pyridoxine. Transfection of HPAECs with S1PL siRNA
decreased S1PL mRNA (.80%) of control levels (data not shown)
and protein expression (, 70%) (Fig. 3A). S1PL siRNA had no
effect on mRNA or protein expression of SphK1 or SphK2 (data
not shown). Further, knockdown of S1PL with siRNA increased
accumulation of S1P (fmol/nmol of cellular lipid P: scrambled
siRNA, 508611; S1PL siRNA, 38876211) (Fig. 3B) and dihydro
S1P (DHS1P) (fmol/nmol of cellular lipid P: scrambled siRNA,
18868; S1PL siRNA, 720665) in cells and enhanced S1P-
induced EC wound healing (Fig. 3D) and migration (Fig. 3E).
Interestingly, treatment of cells with S1PL siRNA slightly
stimulated basal migration of HPAECs in the absence of added
exogenous S1P. In contrast to an increase of S1P or DHS1P in
cells, we did not detect any appreciable accumulation of S1P or
DHS1P in the medium. However, incubation of cells with sodium
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(Fig. 3C). However, under similar experimental conditions,
DHS1P (fmol/nmol of cellular lipid P: scrambled siRNA, 2068;
S1PL siRNA, 1865) levels in the medium were not altered. In
parallel experiments, inhibition of S1PL activity with 4-DP
(500 mM, 5 h) also increased S1P accumulation in cells (,3 fold)
as compared to control cells (fmol/nmol lipid P: control, 390635;
4-DP, 1175658) in the absence of sodium vanadate, and the
addition of sodium vanadate had no effect on 4-DP-dependent
S1P accumulation in cells (Fig. 4A). In the absence of sodium
vanadate, no S1P release was detected in the medium with and
without 4-DP; however, pretreatment of cells with sodium
vanadate (1 mM, 1 h) enhanced S1P levels in the medium either
in the presence or absence of 4-DP (Fig. 4B). 4-DP pretreatment
also enhanced endothelial wound healing (Fig. 4C and 4D). In
these experiments, wound healing by S1Pext served as a positive
control (Fig. 4C and 4D). These results show that increasing
intracellular S1P levels by down-regulation of S1PL expression or
blocking S1PL activity enhances S1P accumulation in cells and
medium and stimulates basal wound healing in HPAECs.
Role of Rac1 and IQGAP1 in [S1P]ext-induced HPAEC
Migration
We have earlier demonstrated that S1P-induced activation of
Rac1 regulates migration of HPAECs [12], and more recently
identified a role for phospholipase D (PLD) dependent activation
of IQGAP1 via Rac1 in hyperoxia-induced reactive oxygen
species production in human lung endothelium [40]. To further
characterize down-stream target(s) of Rac1 in cell migration, we
investigated the role of IQGAP1, a IQ domain protein with a
region containing sequence that has homology to RasGAP [41], in
[S1P]ext mediated wound healing. Exposure of HPAECs to S1Pext
(1 mM) for 15 min induced redistribution of Rac1 and IQGAP1 to
cell periphery as evidenced by immunofluorescence microscopy
(Relative Fluorescence Units: vehicle: Rac1, 100623; IQGAP1,
100629; S1P: Rac1, 250638; IQGAP1 325652) (Fig. 5A). As
shown in Fig. 5B, down-regulation of Rac1 or IQGAP1 with
siRNA (50 nM, 48 h), compared to scrambled siRNA (50 nM,
48 h), attenuated [S1P]ext-induced cell motility. The efficacy of
Rac1 and IQGAP1 siRNA was evaluated by Western blotting of
Rac1 and IQGAP1 that showed greater than 70% knockdown of
the protein expression (Fig. 5C). Activation of Rac1 and IQGAP1
by S1Pext was verified by precipitation of Rac1 bound to GTP
with PAK-1 PBD beads and IQGAP1 tyrosine phosphorylation,
respectively (Fig. 6A and 6B). Next, we investigated whether
Rac1 was upstream of [S1P]ext-induced IQGAP1 activation.
HPAECs were transfected with Rac1 or IQGAP1 siRNA (50 nM,
48 h) and exposed to [S1P]ext (1 mM) for 30 min. As shown in
Fig. 7, Rac1 siRNA almost completely blocked S1P-induced
IQGAP1 redistribution to cell periphery while IQGAP1 siRNA
had no effect on [S1P]ext-dependent Rac1 redistribution to cell
periphery. These data suggest a potential involvement of Rac1 and
IQGAP1 in [S1P]ext-induced HPAEC migration, and IQGAP1 as
a down-stream target of Rac1.
SphK1 siRNA, but not SphK2 siRNA, Attenuates [S1P]ext-
induced Rac1 and IQGAP1 Redistribution to Cell
Periphery
Having established a role for Rac1 and IQGAP1 in [S1P]ext-
induced cell migration, we next investigated the effect of down-
regulation of SphK1 or SphK2 with siRNA on basal and [S1P]ext-
induced redistribution of Rac1 and IQGAP1. HPAECs were
transfected with scrambled, SphK1 or SphK2 siRNA (50 nM,
48 h) prior to S1P challenge, and as shown in Fig. 8A and 8B,
SphK1 siRNA, but not scrambled or SphK2 siRNA, attenuated
[S1P]ext-induced Rac1 and IQGAP1 translocation to cell
Figure 1. CII, inhibitor of SphK, decreases both the migration
of HPAECs in a scratch assay in vitro and the content of S1P in
HPAECs. HPAECs grown to ,95% confluence in 35 mm dishes were
starved for 3 h in 0.1% FBS in EBM-2 without growth factors and treated
with 10 mM of CII. Monolayers were scratched, and challenged with
medium containing 0.1% BSA or 1.0 mM S1P complexed to 0.1% BSA.
A shows the migration of cells into a ‘‘wound’’ that was scratched and
exposedtoS1P. BshowsthedecreaseofS1P content incellsasmeasured
by LC/MS/MS (see Methods) after lipid extraction from harvested cells.
The values are mean 6 S.E.M for three independent experiments each
performed in triplicate (*** - p,0.001 in comparison to T=0 min).
doi:10.1371/journal.pone.0016571.g001
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PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16571Figure 2. Silencing of SphK1, but not SphK2, decreases HPAEC migration by S1P in wound healing ECIS assay. HPAECs (,50%
confluence) grown on 35-mm dishes or on gold electrodes (10
–4 cm
2) were transfected with either scrambled siRNA or SphK1 siRNA or SphK2 siRNA
(25 nM, 72 h), then starved for 3 h in 0.1% FBS in EBM-2 without growth factors. Cell lysates (20 mg total protein) were subjected to SDS-PAGE on
10% precast Tris-Glycine gels and Western blotted with anti-SphK1 (A) and SphK2 (B) antibody as described under ‘‘Experimental procedures’’.
Western blot is representative of three independent experiments. Total RNA was isolated from control and SphK1 siRNA (C) and SphK2 (D)
transfected cells, and Real-time PCR was performed in a Light Cycler using SYBR Green QuantiTect. Control and transfected cells were wounded on
the gold electrodes (E and F) as described under ‘‘Experimental Procedures’’ prior to S1P (1.0 mM) challenge. Measurement of transendothelial
electrical resistance (TER) using an electrical cell substrate impedance-sensing system (ECIS) for 16 h after wounding the cells on the gold electrode
and exposure to 1.0 mM S1P was carried out. Values are the mean 6 S.E.M. for three independent experiments in triplicate.
doi:10.1371/journal.pone.0016571.g002
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PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16571Figure 3. Silencing of S1PL increases intracellular S1P content in HPAECs and stimulates cell migration in an in vitro scratch and in a
wound healing ECIS assay. HPAECs (,50% confluence) grown on 35-mm dishes or on gold electrodes were transfected with either scrambled
siRNA or S1PL siRNA (50 nM, 72 h), then starved for 3 h in 0.1% FBS in EBM-2 without growth factors. A - Cell lysates (20 mg total proteins) were
subjected to SDS-PAGE and Western blotted with anti-S1PL antibody as described under ‘‘Experimental procedures’’. Western blot is representative of
three independent experiments. B,C – S1PL was silenced with siRNA (50 nM, 72 h) then intracellular (B) and extracellular (C) S1P content was
determined by LC/MS/MS. Ortho-vanadate (1 mM) was applied 30 min before lipid extraction. S1P level in the medium was normalized per cellular
phospholipid content. D – HPAECs (,50% confluence) were transfected with either scrambled siRNA or S1PL siRNA (50 nM, 72 h) then wounded on
the gold electrodes as described under ‘‘Experimental Procedures’’ prior to S1P (1.0 mM) challenge. Transendothelial electrical resistance (TER) was
recorded using an electrical cell substrate impedance-sensing system (ECIS) for 16 h. Values are the mean 6 S.E.M. for three independent
experiments in triplicate. E-HPAECs (,50% confluence) were transfected with either scrambled siRNA or S1PL siRNA (50 nM, 72 h) prior to
scratching the cells for migration assay. Scratched cells were challenged with S1P (1.0 mM) for 16 h. The closure of the wound was evaluated as
described under ‘‘Experimental Section’’ 16 h after the wounding of EC monolayer. The values are mean 6 S.E.M. for three independent experiments
in triplicates.
doi:10.1371/journal.pone.0016571.g003
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attenuated S1P-induced Rac1 activation as determined by
precipitation of Rac1 bound to GTP with PAK-1 PBD beads
(Fig. 8C). These results suggest a role for SphK1 in S1Pext-
induced translocation of Rac1 and IQGAP1 to cell periphery in
HPAECs.
Down-regulation of S1PL with siRNA or Inhibition of S1PL
Activity with 4-Deoxypyridoxine Stimulates Rac1 and
IQGAP1 Redistribution to Cell Periphery
We next investigated the effect of knockdown of S1PL
expression or inhibition of S1PL activity on basal and [S1P]ext-
induced redistribution of Rac1 and IQGAP1 to cell periphery and
activation of Rac1. HPAECs either on glass coverslips or 100 mm
dishes were transfected with scrambled or S1PL siRNA (50 nM,
48 h) prior to exposure to media alone or media containing S1P
(1 mM). As shown in Fig. 9A, knockdown of S1PL with siRNA
enhanced redistribution of Rac1 and IQGAP1 to cell periphery
under basal condition (without exogenous S1P). Further, silencing
of S1PL with siRNA dramatically increased Rac1 activation under
basal condition that was similar to [S1P]ext mediated Rac1
activation (Fig. 9B). In S1PL down-regulated cells with siRNA,
stimulation with [S1P]ext did not further enhance the basal Rac1
activation (Fig. 9B). In parallel experiments, Inhibition of S1PL
with 4-DP (500 mM) resulted in a similar activation of Rac1 and
IQGAP1 in the absence of [S1P]ext addition to HPAECs (Fig. 10).
Figure 4. 4-Deoxypyridoxine increases intracellular content of S1P in HPAECs and stimulates cell migration in a wound healing
ECIS assay. HPAECs (,90% confluence) grown on 35-mm dishes or on gold electrodes were starved for 3 h in 0.1% FBS in EBM-2 without growth
factors and treated with 1 mM 4-DP for 6 h in the same medium. A, B – 4-DP increases intracellular content of S1P (A) and S1P release into the
medium (B). Ortho-vanadate was added 30 min before lipid extraction in a fresh medium. S1P content in cells and medium was determined by LC-
MS/MS as described under ‘‘Experimental procedures’’. (C, D) - Control and 4-DP-treated (1 mM for 30 min) cells were wounded on the gold
electrodes as described under ‘‘Experimental Procedures’’ prior to S1P (1 mM) challenge. D shows the changes in TER (ohms) in vehicle and 4-DP or
S1P-treated cells at 4 h after wounding. Values are the mean 6 S.E.M. for three independent experiments.
doi:10.1371/journal.pone.0016571.g004
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16571Figure 5. Silencing of Rac1 and IQGAP1 decreases HPAEC migration in an in vitro scratch assay. HPAECs (,50% confluence) grown on
35-mm dishes or on cover slips were transfected with either scrambled siRNA or Rac1 siRNA or IQGAP1 siRNA (50 nM, 72 h), then starved for 3 h in
0.1% FBS in EBM-2 without growth factors. In A, cells on cover slips were stimulated with 0.1% BSA-complexed S1P (1.0 mM) for 5 min, washed, fixed,
permeabilized, probed with anti-Rac1 antibody and anti-IQGAP1 antibody, and examined by immunofluorescence microscopy using a 660 oil
objective. In B, HPAECs (,50% confluence) were transfected with either scrambled siRNA or Rac1 siRNA or IQGAP1 siRNA (50 nM, 72 h) prior to
scratching the cells for migration assay. Scratched cells were challenged with S1P (1.0 mM) for 16 h. The values are means 6 S.E.M. for three
independent experiments each done in triplicates. C - Cell lysates (20 mg total proteins) were subjected to SDS-PAGE and Western blotted with anti-
Rac1 and anti-IQGAP1 antibody as described under ‘‘Experimental procedures’’. Western blot is representative of three independent experiments.
doi:10.1371/journal.pone.0016571.g005
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PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16571Taken together, these results demonstrate that increased S1P levels
in cells of S1PL siRNA or 4-DP treated cells stimulate Rac1 and
IQGAP1 that is independent of [S1P]ext.
Pertussis Toxin Attenuates [S1P]ext and S1PL siRNA
Mediated Redistribution of Rac1 and IQGAP1 in HPAECs
Our earlier studies demonstrated that S1P1 is the predominant
receptor expressed in HPAECs and the involvement of Gi in
human lung EC migration by transducing signals initiated by S1P
activation of S1P1 [12]. Here, we investigated the effect of pertussis
toxin (PTx) on [S1P]ext - and S1PL siRNA-induced cell migration.
HPAECs transfected with scrambled or S1PL siRNA (50 nM, 48h)
were treated with PTx (100 ng/ml, 16 h) prior to challenge with
media alone or media plus [S1P]ext (1 mM). PTx significantly
blocked basal-, [S1P]ext- and S1PL siRNA-mediated redistribution
of Rac1 (Fig. 11A) and IQGAP1 (Fig. 11B). These results show
that the activation of Rac1 and IQGAP1 due to S1P accumulation
by S1PL siRNA is sensitive to PTx suggesting involvement of Gi
and S1P receptors.
Antagonist of S1P1 and 3, but not S1P2, Block S1PL siRNA-
or 4-Deoxypyridoxine- Mediated basal Cell Migration
Having established a role for SphK1 and S1PL in S1P-mediated
migration of HPAECs, we next studied the role of S1P1-3 on basal,
[S1P]ext-, S1PL siRNA - or 4-DP-induced cell migration.
Stimulation of EC migration by [S1P]ext or by silencing the
S1PL was blocked by VPC23019 (10 mM), an antagonist of S1P1
and 3 [42] (Fig. 12). In contrast to VPC23019, pretreatment of
cells with JTE-013, an antagonist of S1P2, had no significant effect
on migration of HPAECs initiated by [S1P]ext or by S1PL
inhibition (data not shown). These results suggest that stimulation
of cell migration by [S1P]ext or intracellularly generated S1P by
S1PL siRNA requires coupling to S1P1 and/or 3 in HPAECs.
S1PL siRNA or 4-Deoxypyridoxine-Mediated Cell
Migration and Redistribution of Rac1 and IQGAP1 Involve
Secretion of Intracellular S1P
Having established that S1PL siRNA or 4-DP treatment
increases S1P levels in cells and stimulates endothelial cell motility,
we next evaluated whether these effects were mediated by an
autocrine pathway of S1P secretion and signaling via S1P1 and/or 3
by using a highly specific anti-S1P monoclonal antibody (mAb)
[33,34]. This S1P specific antibody, at a concentration of 150 mg/
ml, has been shown to effectively neutralize about 2 mMo f
extracellular S1P released or added into the condition medium
[33]. As shown in Fig. 13A, addition of the anti-S1P mAb
(150 mg/ml) to the medium abrogated S1Pext or 4-DP induced cell
migration measured by ECIS wound healing assay. Addition of an
isotype-matched mouse IgGk1 (150 mg/ml) to the medium, under
same experimental condition, had no significant effect on [S1P]ext
- or 4-DP-induced wound healing of HPAECs. (Fig. 13A).
Similarly, anti-S1P mAb effectively blocked [S1P]ext- or 4-DP-
dependent translocation of Rac1 (Fig. 13B) and IQGAP1
(Fig. 13C) to cell periphery. These data show that cellular
responses due to elevation of cellular S1P by S1PL siRNA or 4-
DP, in part, are mediated by the ‘‘inside-out’’ signaling mechanism
and ligation to S1P receptors on the cell surface.
Discussion
Endothelial cell migration is a key component of angiogenesis
and an important physiological response for normal vascular
development; however, is abnormal in pathophysiological condi-
tions such as age-related wet macular degeneration and tumor
angiogenesis. Among the plethora of growth factors that regulate
endothelial cell angiogenic responses, S1P is probably the most
potent [9] and is the ligand for the family of S1P1–5 G-protein
coupled receptors [2–7]. While evidence for extracellular action of
S1P via its receptors in cell migration is compelling, it is unclear if
intracellular generation of S1P is necessary for [S1P]ext function.
In this study, we have evaluated the role of intracellular S1P
generation and the balance between its synthesis and degradation
in regulating [S1P]ext-mediated endothelial cell migration. The
results presented here provide evidence that modulation of SphK1
and S1PL, enzymes involved in the conversion of Sph to S1P and
breakdown of S1P to hexadecenal and ethanolamine phosphate,
respectively, exhibit a profound effect on cell migration. Our
results further suggest that exogenous S1P is not sufficient by itself
to exert a full effect on EC migration as evidenced by data showing
Figure 6. S1P induces Rac1 activation and IQGAP1 tyrosine phosphorylation in HPAECs. HPAECs (,90% confluence) grown on 35-mm
dishes were starved for 3 h in 0.1% FBS in EBM-2 without growth factors and treated with S1P (1 mM) for 5 min. Activated Rac1 was
immunoprecipitated from total cell lysates (500 mg of total protein) from control and S1P (1 mM) treated cells using PAK-1 PBD agarose beads as
described under ‘‘Experimental Procedures’’. A, Rac-1-GTP bound to PAK-1 PBD were separated by SDS-PAGE, transferred to nitrocellulose, and
probed with anti-Rac1 antibody. B, IQGAP1 was immunoprecipitated from total cell lysates (500 mg of total protein) from control and S1P (1 mM)
treated cells using anti-IQGAP1 antibody. Immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-p-Tyr
antibody. Shown is a representative blot from three independent experiments.
doi:10.1371/journal.pone.0016571.g006
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SphK1 with siRNA attenuated S1P-induced migration.
Earlier studies have shown that S1P-induced EC migration is
regulated by several distinct signaling pathways and depends on
the cell type, type of S1P receptor, and concentrations of S1P. S1P
stimulates cell migration through extracellular ligation of its
receptors, S1P1 and S1P3 coupled to Gai,G q or G12/13 and
activation of Rac, MAPKs and PI3K [43]. In contrast to S1P1 and
S1P3, S1P2 seems to have an opposing effect on EC migration as
blocking S1P2 up-regulated S1P-induced migration in vascular
ECs and smooth muscle cells [44,45]. Interestingly, S1P1 is
essential for embryogenesis and vessel maturation as S1P1 2/2
null mice die at day 14 of embryogenesis [46]. We have earlier
demonstrated in human lung endothelial cells that S1P signals
through S1P1 and Gi to activate PKC-e and subsequently, a
PLD2RPKC-fRRac1 cascade to stimulate migration [12].
Although, we have demonstrated a role for PI3K in EC motility
[47], blocking PI3K with LY294002 had no effect on S1P-induced
PLD activation [12] indicating PLD- and PI3K-dependent
pathways of S1P mediated cell motility.
An important finding of the present study is that endogenous
S1P production is essential for [S1P]Ext mediated EC migration. In
ECs and other cell types, SphK1 and/or SphK2 catalyze the
phosphorylation of sphingosine to S1P and accumulation of S1P is
a balance between synthesis and degradation mediated by S1PL,
lipid phosphate phosphatases and S1P phosphatases [19–22]. We
observed that blocking SphK1 reduced intracellular S1P gener-
ation and S1P-induced cell migration and resistance while
knockdown or attenuation of S1PL enhanced S1P levels and
potentiated migration (Figs. 1, 2, 3). These results are in
agreement with our earlier study demonstrating the ability of
human lung ECs to convert exogenously added S1P to sphingosine
by LPPs on the cell surface, followed by the rapid uptake of
sphingosine into the cell and conversion to S1P by SphK1 [19].
Thus, in addition to its extracellular action, endogenous S1P
generation is essential for sustained S1P-mediated cell migration
likely due to a recycling effect whereby S1P is initially
dephosphorylated and then sent back to SphK1 for phosphory-
lation to S1P and eventual release. Although human lung ECs
rapidly take up exogenous sphingosine and converts it to S1P in
the cell, EC migration is more pronounced with exogenous S1P
(1 mM) as compared to exogenous sphingosine (1 mM). This
discordant effect of exogenous S1P and sphingosine was also
observed in changes in electrical resistance and phosphorylation of
ERK1/2 in lung ECs described earlier [31].
Interestingly, S1P delivered as a liposome, induced non-
directional cell movement, in contrast to directional cell motility
by extracellular S1P in L6, COS7 and SH-SY5Y cell types [48]
indicating translocation of SphK1 to certain specialized areas of
the cell such as membrane ruffles in the formation of cell polarity.
However, the mechanism(s) of extracellular vs. liposomal S1P
action on formation of cell polarity and random migration as well
as role for S1P receptors were not addressed. In a recent study, a
role for SphK1 in nitric oxide-mediated human endothelial cell
migration and tube formation was demonstrated; however, the
contribution of endogenous S1P was not demonstrated [49].
Similarly, TGF-b stimulated collagen production in cardiac
fibroblasts is critically dependent on intracellular S1P generated
by SphK1 [50]. While many studies including the results presented
here strongly support a role for SphK1 in cellular functions such
motility and collagen production, a recent report suggests that
SphK2 deficiency contributes to reduced S1P accumulation in
lymphoid tissues and attenuated T and B cell lymphopenia [51].
Thus, role of SphK1 and/or SphK2 may vary in different cell
types and tissues.
Because our results show a requirement for intracellularly
generated S1P in extracellular S1P-mediated cell migration, it was
important to delineate the mechanism. S1P generated inside the
cell can act as an intracellular second messenger as evidenced by
increased DNA synthesis [52] and calcium mobilization from
internal stores [2,3] or signal ‘inside-out’ via S1P receptors [25].
However, the intracellular target(s) mediating these S1P responses
have not been well characterized. Recently, interaction between
SphK2/S1P and histone deacetylases in breast cancer cells [15]
and S1P as a missing co-factor for E3 ubiquitin ligase TRAF2 in
HEK 293 cells [28] were shown. Our results, using a two prong
approach of pretreatment with PTx or anti-S1P antibody, show
that intracellular S1P regulates cell motility through an ‘inside-out’
signaling pathway. The increased redistribution of Rac1 and
Figure 7. Rac1 siRNA attenuates translocation of IQGAP1 to the
cell periphery. HPAECs (,50% confluence) grown on coverslips were
transfected with either scrambled siRNA or Rac1 siRNA or IQGAP1 siRNA
(50 nM, 72 h), starved for 3 h in 0.1% FBS in EBM-2 without growth
factors and treated with S1P (1 mM) for 5 min. Cells were washed, fixed,
permeabilized, probed with anti-IQGAP1 or anti-Rac1 antibodies, and
examined by immunofluorescence microscopy using a 660 oil
objective.
doi:10.1371/journal.pone.0016571.g007
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PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e16571Figure 8. SphK1 siRNA, but not SphK2 siRNA, attenuates Rac1 activation and IQGAP1 translocation to cell periphery of HPAECs.
HPAECs (,50% confluence) grown on 35-mm dishes or cover slips were transfected with either scrambled siRNA or SphK1 siRNA or SphK2 siRNA
(25 nM, 72 h), then starved for 3 h in 0.1% FBS in EBM-2 without growth factors. Cells on cover slips were stimulated with 0.1% BSA-complexed S1P
(1.0 mM) for 5 min, washed, fixed, permeabilized, probed with anti-Rac1 antibody (A) and anti-IQGAP1 (B) antibody, and examined by
immunofluorescence microscopy using a 660 oil objective. In C, activated Rac1 was immunoprecipitated from total cell lysates (500 mg of total
protein) from control, transfected and S1P (1.0 mM) treated cells using PAK-1 PBD agarose beads as described under ‘‘Experimental Procedures’’. Rac-
1-GTP bound to PAK-1 PBD were separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-Rac1 antibody. Shown is a
representative blot from three independent experiments.
doi:10.1371/journal.pone.0016571.g008
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S1PL was PTx sensitive suggesting release and signaling of S1P
from outside the cell involving S1P receptors. Blocking of S1P1
and S1P3 activation by VPC23019 attenuated S1P as well as S1PL
siRNA mediated increase of endothelial electrical resistance
confirming involvement of these two S1P receptors in barrier
regulation. Further, the ability of the anti-S1P antibody to
neutralize S1P’s effects on endothelial layer resistance (Fig. 13A)
confirms an extracellular signaling role for S1P and is consistent
with the ability of the anti-S1P antibody to block the S1P/TGF-b
axis with regard to collagen expression in cardiac fibroblast [50].
Interestingly, treatment of cells with anti-S1P antibody slightly
reduced basal electrical resistance even in the absence of
exogenous S1P or 4-DP (Fig. 13A). The ‘inside-out’ signaling
was further substantiated in studies where over-expression of LPP-
1 wild type attenuated S1PL siRNA- or 4-DP-mediated increase in
electrical resistance (data not shown). This is the first time that S1P
has been shown to utilize an ‘inside-out’ signaling mechanism in
cell motility. These findings suggest a role for basal S1P release
through ‘inside-out’ signaling in the maintenance of endothelial
barrier integrity. Release of intracellularly generated S1P to cell
media may involve members of the ABC transporter family,
ABCC1 [29], ABCA1 [53] and ABCG2 [54]; however, other
mechanisms must be operating as genetic knockouts of ABCC1,
ABCA1, and ABCA7 do not result in lowered plasma S1P levels.
Recently, Spns2 protein has been identified as an S1P transporter
in zebra fish [55]. At present it is unclear if ABC transporter
protein(s) or Spns2 or both are involved in regulating ‘inside-out’
S1P secretion in human lung endothelial cells that needs to be
determined. 4-DP treated cells mitigated Rac1 and IQGAP1
redistribution to cell periphery and changes in electrical resist-
ance (Figure 13). This demonstrates that anti-S1P antibody
is able to neutralize exogenous or endogenous S1P secreted to
cell culture media and prevent S1P mediated ‘inside-out’ signa-
ling. The concentration of anti-S1P antibody (150 mg/mL)
that effectively blocked extracellular or secreted S1P-induced
Rac1/IQGAP1 redistribution to cell periphery and increase in
electrical resistance measurements suggests a substantial release of
Figure 9. Silencing of S1PL stimulates Rac1 activation and IQGAP1 translocation to cell periphery of HPAECs. HPAECs (,50%
confluence) grown on 35-mm dishes or cover slips were transfected with either scrambled siRNA or S1PL siRNA (50 nM, 72 h), then starved for 3 h in
0.1% FBS in EBM-2 without growth factors. A-Cells on cover slips were stimulated with 0.1% BSA-complexed S1P (1.0 mM) for 5 min, washed, fixed,
permeabilized, probed with anti-Rac1 antibody and anti-IQGAP1 antibody, and examined by immunofluorescence microscopy using a 660 oil
objective. B - Activated Rac1 was immunoprecipitated from total cell lysates (500 mg of total protein) from control, transfected, and S1P (1.0 mM)
treated cells using PAK-1 PBD agarose beads as described under ‘‘Experimental Procedures’’. Rac-1-GTP bound to PAK-1 PBD was separated by SDS-
PAGE, transferred to nitrocellulose, and probed with anti-Rac1 antibody. Shown is a representative blot from three independent experiments.
doi:10.1371/journal.pone.0016571.g009
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demonstrates that the released S1P is likely rapidly degraded after
triggering S1P receptor-mediated signaling events by the action of
phosphatases that produce Sph for recycling into a new pool of
releasable S1P by providing substrate for intracellular SphKs 1
and 2.
Figure 10. 4-Deoxypyridoxine stimulates translocation of Rac1 and IQGAP1 to the cell periphery. HPAECs (,90% confluence) grown on
coverslips were starved for 3 h in 0.1% FBS in EBM-2 without growth factors then treated with 4-DP (1 mM) for 6 h, with or without final treatment
with S1P (1 mM) for 5 min. Cells were washed, fixed, permeabilized, probed with anti-Rac1 antibody and anti-IQGAP1 antibody, and examined by
immunofluorescence microscopy using a 660 oil objective. Shown is a representative micrograph from three independent experiments.
doi:10.1371/journal.pone.0016571.g010
Figure 11. Pertussis toxin attenuates translocation of Rac1 and IQGAP1 to cell periphery induced by S1P or by silencing of S1PL.
HPAECs (,50% confluence) grown on cover slips were transfected with either scrambled siRNA or S1PL siRNA (50 nM, 72 h), then treated with
Pertussis toxin (100 ng/ml) for 16 h in 2% FBS in EBM-2 without growth factors. Cells were stimulated with 0.1% BSA-complexed S1P (1.0 mM) for
5 min, washed, fixed, permeabilized, probed with anti-Rac1 (A) or anti-IQGAP1 (B) antibodies, and examined by immunofluorescence microscopy
using a 660 oil objective.
doi:10.1371/journal.pone.0016571.g011
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Standards and Reagents
S1P, DHS1P, a 17-carbon analog of S1P (C17-S1P) were
obtained from Avanti Polar Lipids (Alabaster, AL, USA). Rac1
activation assay kit was obtained from Upstate (Temecula, CA,
USA). Formaldehyde (36.5%) was obtained from Sigma (St. Louis,
MO, USA). Lysis buffer was purchased from Cell Signaling
Technology Inc. (Danvers, MA, USA). Protease inhibitor cocktail
tablets (EDTA-free Complete) were from Roche Diagnostics
(Indianapolis, IN, USA). Aprotinin and phosphatase inhibitor
cocktail 1 were from Sigma-Aldrich (St. Louis, MO, USA).
Inhibitors—VPC23019 were obtained from Avanti Polar Lipids
(Alabaster, AL, USA). Pertussis toxin was purchased from
Calbiochem (La Jolla, CA, USA). 4-Deoxypyridoxine was
purchased from Sigma (St. Louis, MO, USA). SphK inhibitor,
2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole (CII), was ob-
tained from Cayman (Ann Arbor, MI, USA).
siRNA
Scrambled and target siRNA for SphK1, SphK2, and S1P1
were obtained from Dharmacon (Lafayette, CO, USA). siRNA for
S1PL, Rac1 and IQGAP1 were from Santa-Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA).
Antibodies
Anti-IQGAP1, anti-phospho-ERK, and anti-S1P1 antibody
were purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA). Anti-S1P2, anti-S1P3, anti-S1P4, anti-S1P5
antibodies were purchased from Exalpha Biological Inc. (May-
nard, MA, USA); anti-SphK1 was obtained from Abcam, anti-
SphK2 antibody were kindly provided by Dr. Taro Okada from
Department of Molecular and Cellular Biology (Kobe University
Graduate School of Medicine, Japan). Anti-Rac1 antibody was
from BD Biosciences Pharmingen (San Jose, CA, USA); anti-b-
actin antibody was from Sigma (St. Louis, MO, USA). Murine
anti-S1P monoclonal antibodies (LT1002) and control isotype-
matched IgGk1 antibodies came from Lpath, Inc. [33,34].
Cell Culture
HPAECs (passage number 3) were purchased from Cambrex
Inc. (Walkersville, MD, USA) and cultured in complete endothe-
lial growth medium (EGM)-2 medium [19]. The cells (passage
number 5-8) in 35-mm or 100-mm dishes or glass coverslips were
used for all the experiments.
Endothelial Cell Migration
HPAEC were cultured in 12- or 6-well plates to ,95%
confluence and then starved in the serum-free EGM-2 medium for
1–3 h or in EBM-2 medium containing 1% FBS for 18–24 h. The
cell monolayer was wounded by scratching across the monolayer
with a 10 ml standard sterile pipette tip. The scratched monolayer
was rinsed twice with serum-free medium to remove cell debris
and incubated with varying concentrations of S1P. The area
(,1c m
2 total) in a scratched area was recorded at 0 h and 16–
24 h using a Hamamatsu digital camera connected to the Nikon
Eclipse TE2000-S microscope with 610 objective and MetaVue
software (Universal Imaging Corp., PA, USA) images were
analyzed by the Image J software. The effect of S1P and other
agents on endothelial cell migration/wound healing was quantified
by calculating the percentage of the free area not occupied by cells
compared to an area of the initial wound that was defined as
closure of wounded area.
Electrical Cell Substrate Impedance Sensing (ECIS) Assay
HPAEC were cultured in 8-well ECIS electrode arrays (8W1E,
Applied Biophysics, NY, USA) to ,95% confluence and starved in
the serum-free EBM-2 medium for 1–3 h. An elevated field (3 V
at 40,000 Hz for 10 sec) was applied to wound the cells on the
electrode. S1P (1 mM) was added and endothelial wound healing
was monitored for 10–20 h by measuring the transendothelial
electrical resistance using the ECIS equipment [35,36]. In all
experiments S1P was complexed with 0.1% BSA.
Rac1 Activation Assay
HPAECs were cultured in 100 mm dishes to ,50% confluence
for siRNA transfection or to ,95% confluence for adenoviral
infection or inhibitor treatment. Cells were starved in EBM-2
medium containing 0.1% FBS for 3 h prior to stimulation with
S1P for 5–15 min, cell lysates were subjected to immunoprecip-
itation with PAK-1 PBD and Rac1 activation was evaluated using
the Rac1 Activation Assay Kit as per the manufacturer’s
instruction (Upstate, Temecula, CA, USA).
Western Blot Analysis
HPAECs were cultured in 6-well plates or 60 mm dishes to
,95% confluence and starved for 3 h in EBM-2 medium
containing 0.1% FBS. Cells were stimulated with S1P (100–
1000 nM) for 5–60 min, washed with PBS and lysed with 100–
300 ml lysis buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100,
2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate,
1m M N a 3VO4,1 mg/ml leupeptin, 1 mg/ml aprotinin and
protease inhibitors from EDTA-free Complete tablets (Roche
Applied Science, Indianapolis, IN, USA). Cell lysates were cleared
Figure 12. Antagonist of S1P1 and S1P3, but not S1P2, blocks
HPAEC migration induced by S1P and S1PL silencing in a
wound healing ECIS assay. HPAECs (,50% confluence) grown on
gold electrodes were transfected with either scrambled siRNA or S1PL
siRNA (50 nM, 72 h), then starved for 3 h in 0.1% FBS in EBM-2 without
growth factors. Control and transfected cells were wounded on the
gold electrodes as described under ‘‘Experimental Procedures’’ prior to
VPC23019 (10 mM for 15 min) and following S1P (1.0 mM) challenge.
Transendothelial electrical resistance (TER) was recorded for 16 h.
Values are the mean 6 S.E.M. for three independent experiments each
performed in triplicates.
doi:10.1371/journal.pone.0016571.g012
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Laemmli sample buffer for 5 min. Cell lysates (20–30 mg protein)
were separated on 10% or 4–20% SDS-PAGE, transferred to
PVDF membranes, blocked in TBST containing 5% BSA prior to
incubation with primary antibody (1:1000 dilution) overnight.
After blocking, washing and incubation with appropriate second-
ary antibody, blots were developed using an ECL chemilumines-
cence kit. Western blots were scanned by densitometry and
integrated density of pixels in identified areas was quantified using
Image Quant version 5.2 software (Molecular Dynamics, CA,
USA).
Immunofluorescence Microscopy
HPAECs grown on coverslips (18-mm) or chamber slides were
starved for 3 h in EBM-2 containing 1% FBS prior to treatment
with S1P (1 mM) for 5–15 min. Cells were fixed in 3.7%
formaldehyde in PBS for 10 min, washed three times with PBS,
permeabilized with methanol for 4 min at 220u C, blocked with
2% BSA in TBST, incubated for 1 h with appropriate primary
antibody (1:200 dilution), washed with TBST, and stained for 1 h
with secondary antibody (1:200 dilution) in TBST containing 2%
BSA. Cells were examined using a Nikon Eclipse TE2000-S
immunofluorescence microscope and a Hamamatsu digital
camera with660 oil immersion objective and Meta Vue software.
RNA Isolation and Real Time RT-PCR
Total RNA was isolated from HPAECs grown on 35-mm dishes
using TRIzolH reagent according to the manufacturer’s instruction.
iQ SYBR Green Supermix was used to do the real time
measurements using iCycler by BioRad. 18S (sense, 59-GTAA-
CCCGTTGAACCCCATT-39, and antisense, 59- CCATC-
CAATCGGTAGTAGCG-39) was used as a housekeeping gene
to normalize expression.Thereaction mixture consisted of0.3 mgo f
total RNA (target gene) or 0.03 mg of total RNA (18S rRNA),
12.5 ml of iQ SYBR Green, 2 ml of cDNA, 1.5 mM target primers,
or 1 mM 18S rRNA primers, in a total volume of 25 ml. For all
samples, reverse transcription was carried out at 25uC for 5 min,
followed by cycling to 42uC for 30 min and 85uC for 5 min with
iScriptcDNA synthesiskit.Amplicon expression ineachsample was
normalized to its 18S rRNA content. The relative abundance of
target mRNA in each sample was calculated as 2 raised to the
negative ofitsthresholdcyclevaluetimes10
6 afterbeingnormalized
to the abundance of its corresponding 18S rRNA (housekeeping
gene), (2
-(primer Threshold Cycle)/2
-(18 S Threshold Cycle)x1 0
6). All primers
were designed by inspection of the genes of interest using Primer 3
software. Negative controls, consisting of reaction mixtures
containing all components except target RNA, were included with
each of the RT-PCR runs. To verify that amplified products were
derived from mRNA and did not represent genomic DNA
contamination, representative PCR mixtures for each gene were
run in the absenceof the RT enzymeafter first being cycled to 95uC
for 15 min. In the absence of reverse transcription, no PCR
products were observed.
siRNA Transfection
HPAECs grown to ,50% confluence in 6-well plates or
chamber slides were transfected with Gene SilencerH (Gene
Therapy System, Inc. San Diego, CA, USA) transfecting agent
containing scrambled siRNA (50 nM) or siRNA for target proteins
(50 nM) in serum-free EBM-2 medium according to manufactur-
er’s recommendation. To optimize conditions for efficient
transfection, HPAECs were transfected with Fl-Luciferase GL2
Duplex siRNA (Target Sequence: 59-CGTACGCGGAA-
TACTTCGA-39, Dharmacon, CO, USA) as a positive control.
After 3 h transfection, 1 ml of fresh complete EGM-2 medium
containing 10% FBS was added, cells were cultured for additional
72 h, and analyzed for mRNA level by real time PCR or protein
expression by Western blotting. Scrambled siRNA control or
siRNA transfected cells were subjected to scratch or wound
healing experiments as described earlier.
Lipid Extraction and Sample Preparation for LC/MS/MS
Cellular lipids were extracted by a modified Bligh and Dyer
procedure with the use of 0.1N HCl for phase separation as
described in [31]. C17-S1P (40 pmol) was employed as internal
standard, and was added during the initial step of lipid extraction.
The extracted lipids were dissolved in methanol/chloroform
(4:1, v/v), and aliquots were taken to determine the total
phospholipid content as described [37]. Samples were concen-
trated under a stream of nitrogen, re-dissolved in methanol,
transferred to auto sampler vials, and subjected to S1P-DHS1P
LC/MS/MS analysis.
Analysis of Sphingoid Base-1-Phosphates
Analyses of sphingoid base-1-phosphates were performed by
electrospray ionization tandem mass spectrometry (ESI-LC/MS/
MS). The instrumentation employed was an API4000 Q-trap
hybrid triple quadrupole linear ion-trap mass spectrometer
(Applied Biosystems, Foster City, CA, USA) equipped with a
turboionspray ionization source interfaced with an automated
Agilent 1100 series liquid chromatograph and autosampler
(Agilent Technologies, Wilmington, DE, USA). S1P and DHS1P
were analyzed as bis-acetylated derivatives with C17-S1P as the
internal standard employing reverse-phase HPLC separation,
negative ion ESI, and MRM analysis. Details of this approach are
described in [38].
Statistical Analysis
Analysis of variance and Student-Newman-Keul’s test were
used to compare means of two or more different treatment groups.
The level of significance was set to p,0.05 unless otherwise stated.
Results are expressed as mean 6 S.E. M.
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Figure 13. S1P antibodies decrease S1P- and 4-Deoxypyridoxine-induced HPAEC migration. HPAECs (,90% confluence) grown on gold
electrodes or coverslips were starved for 3 h in 0.1% FBS in EBM-2 without growth factors. A -Cells were treated with 4-DP (1 mM for 30 min) then
wounded on the gold electrodes as described under ‘‘Experimental Procedures’’ prior to the addition of isotype-matched control IgGk1 or anti-S1P
antibody (150 mg/ml) and S1P (1 mM) challenge. Transendothelial electrical resistance was recorded for 16 h. Values are the mean 6 S.E.M. for three
independent experiments each performed in triplicate. B,C - Cells on cover slips were treated with 4-DP (1 mM) and anti-S1P antibody for 6 h, then
stimulated with 0.1% BSA-complexed S1P (1.0 mM for 5 min), washed, fixed, permeabilized, probed with anti-Rac1 antibody (B) or anti-IQGAP1
antibody (C), and examined by immunofluorescence microscopy using a 660 oil objective. Shown is a representative micrograph from several
independent experiments.
doi:10.1371/journal.pone.0016571.g013
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